CHICAGO (Reuters) – Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. The treatment, called... More »
(Reuters) – More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc’s experimental gene-modifying immunotherapy in a small, early stage study, according to... More »
We use cookies!
By using this site you agree to the use of cookies, more info.